CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

29 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

09 Mar 2023 17:09:03 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

08 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

12 Dec 2022 08:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

12 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

29 Nov 2022 09:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

21 Nov 2022 09:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

07 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting

03 Nov 2022 09:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022

18 Oct 2022 09:00:02 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

31 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

10 Jun 2022 03:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022

01 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells

16 May 2022 16:05:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

12 May 2022 10:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors

11 May 2022 16:00:00 By Nasdaq GlobeNewswire